These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 29384380)

  • 1. High-Content Surface and Total Expression siRNA Kinase Library Screen with VX-809 Treatment Reveals Kinase Targets that Enhance F508del-CFTR Rescue.
    Perkins LA; Fisher GW; Naganbabu M; Schmidt BF; Mun F; Bruchez MP
    Mol Pharm; 2018 Mar; 15(3):759-767. PubMed ID: 29384380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR.
    Lopes-Pacheco M; Silva IAL; Turner MJ; Carlile GW; Sondo E; Thomas DY; Pedemonte N; Hanrahan JW; Amaral MD
    Biochem Pharmacol; 2020 Oct; 180():114133. PubMed ID: 32628927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
    Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
    Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
    Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simple image-based no-wash method for quantitative detection of surface expressed CFTR.
    Larsen MB; Hu J; Frizzell RA; Watkins SC
    Methods; 2016 Mar; 96():40-45. PubMed ID: 26361332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface.
    Eckford PD; Ramjeesingh M; Molinski S; Pasyk S; Dekkers JF; Li C; Ahmadi S; Ip W; Chung TE; Du K; Yeger H; Beekman J; Gonska T; Bear CE
    Chem Biol; 2014 May; 21(5):666-78. PubMed ID: 24726831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.
    Chin S; Hung M; Won A; Wu YS; Ahmadi S; Yang D; Elmallah S; Toutah K; Hamilton CM; Young RN; Viirre RD; Yip CM; Bear CE
    Mol Pharmacol; 2018 Aug; 94(2):917-925. PubMed ID: 29903751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.
    Van Goor F; Hadida S; Grootenhuis PD; Burton B; Stack JH; Straley KS; Decker CJ; Miller M; McCartney J; Olson ER; Wine JJ; Frizzell RA; Ashlock M; Negulescu PA
    Proc Natl Acad Sci U S A; 2011 Nov; 108(46):18843-8. PubMed ID: 21976485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanistic Approaches to Improve Correction of the Most Common Disease-Causing Mutation in Cystic Fibrosis.
    Bali V; Lazrak A; Guroji P; Matalon S; Bebok Z
    PLoS One; 2016; 11(5):e0155882. PubMed ID: 27214033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
    Brewington JJ; McPhail GL; Clancy JP
    Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.
    Capurro V; Tomati V; Sondo E; Renda M; Borrelli A; Pastorino C; Guidone D; Venturini A; Giraudo A; Mandrup Bertozzi S; Musante I; Bertozzi F; Bandiera T; Zara F; Galietta LJV; Pedemonte N
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
    Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
    EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels.
    Kopeikin Z; Yuksek Z; Yang HY; Bompadre SG
    J Cyst Fibros; 2014 Sep; 13(5):508-14. PubMed ID: 24796242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients.
    Kmit A; Marson FAL; Pereira SV; Vinagre AM; Leite GS; Servidoni MF; Ribeiro JD; Ribeiro AF; Bertuzzo CS; Amaral MD
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1323-1331. PubMed ID: 30716472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of novel F508del-CFTR traffic correctors among triazole derivatives.
    Bacalhau M; Ferreira FC; Kmit A; Souza FR; da Silva VD; Pimentel AS; Amaral MD; Buarque CD; Lopes-Pacheco M
    Eur J Pharmacol; 2023 Jan; 938():175396. PubMed ID: 36410419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Full Rescue of F508del-CFTR Processing and Function by CFTR Modulators Can Be Achieved by Removal of Two Regulatory Regions.
    Uliyakina I; Botelho HM; da Paula AC; Afonso S; Lobo MJ; Felício V; Farinha CM; Amaral MD
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32630527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry.
    Sinha C; Zhang W; Moon CS; Actis M; Yarlagadda S; Arora K; Woodroofe K; Clancy JP; Lin S; Ziady AG; Frizzell R; Fujii N; Naren AP
    Chembiochem; 2015 Sep; 16(14):2017-22. PubMed ID: 26227551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).
    Matthes E; Goepp J; Carlile GW; Luo Y; Dejgaard K; Billet A; Robert R; Thomas DY; Hanrahan JW
    Br J Pharmacol; 2016 Feb; 173(3):459-70. PubMed ID: 26492939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.
    Ren HY; Grove DE; De La Rosa O; Houck SA; Sopha P; Van Goor F; Hoffman BJ; Cyr DM
    Mol Biol Cell; 2013 Oct; 24(19):3016-24. PubMed ID: 23924900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.